Comparative Pharmacology
Head-to-head clinical analysis: AMPHETAMINE SULFATE versus METADATE CD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHETAMINE SULFATE versus METADATE CD.
AMPHETAMINE SULFATE vs METADATE CD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases presynaptic release of dopamine and norepinephrine, blocks reuptake, and inhibits monoamine oxidase, resulting in CNS stimulation.
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. The precise mechanism for treating ADHD is not fully understood.
5–60 mg/day orally in 1–3 divided doses, initial 5 mg once or twice daily, increase by 5 mg weekly.
20-60 mg orally once daily in the morning
None Documented
None Documented
Terminal elimination half-life: 10-13 hours in adults with acidic urine; prolonged to 16-34 hours with alkaline urine. In children, half-life is typically shorter (6-8 hours).
Terminal elimination half-life: 6.8 hours (range 4.5-10.3 hours) for methylphenidate; clinical context: supports twice-daily dosing regimen
Renal excretion of unchanged amphetamine (approximately 30-40%) and its metabolites; urinary pH-dependent: acidic urine enhances elimination (up to 70% unchanged), alkaline urine reduces it. Minor biliary/fecal elimination (<10%).
Renal: 78-97% as metabolites (primarily ritalinic acid), unchanged drug <1%; fecal: <2%
Category D/X
Category C
CNS Stimulant
CNS Stimulant